ClinicalTrials.gg
RecruitingNCT06931652E-REVRIUpdated Jun 15, 2026

Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab

A Phase 2 interventional study of Epcoritamab in Primary CNS Lymphoma (PCNSL), sponsored by The Lymphoma Academic Research Organisation. Recruiting at 13 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by The Lymphoma Academic Research Organisation · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this phase 2 study is to evaluate the efficacy and safety of epcoritamab in subjects with relapsed or refractory primary diffuse large B-cell lymphoma of the Central Nervous System treated with rituximab and lenalidomide.

Read the detailed description

Primary CNS DLBCL has an altered prognostic compared to systemic DLBCL mostly due to an increased relapse rate. PCNSL patients for whom the global prognostic remains poor, calling for improved treatment at relapse.

Considering the good results of R2 regimen in R/R PCNSL and the efficacy and favorable safety profile of epcoritamab in R/R systemic DLBCL, the addition of Epcoritamab to the combination of R2 might significantly improve the prognosis of PCNSL patients at relapse. In addition, it is expected that IMiDs could potentially increase the efficiency of epcoritamab by stimulating the immune system.

02

Conditions studied

  • Primary CNS Lymphoma (PCNSL)

Keywords

  • primary CNS lymphoma
  • treatment for primary CNS lymphoma
  • epcoritamab treatment
  • rituximab and lenalidomide treatment
  • Primary CNS Lymphoma (PCNSL)
03

In context

Lead sponsor

The Lymphoma Academic Research Organisation is the lead sponsor of 60 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject (or their legally acceptable representative/trusted person) who understand and voluntarily signs and dates an form prior to any study-specific assessments/procedures being conducted.
  2. Subject ≥ 18 years old at the time of signing the informed consent form (ICF)
  3. Confirmed histology of primary diffuse large B-cell lymphoma of the CNS (according to the 2022 WHO classification) or confirmed cytology of primary vitreoretinal diffuse large B-cell lymphoma, with CD20 positivity in immunohistochemical staining or flow cytometry at any point in the disease history.
  4. Subjects with (R/R) PCNSL or PVRL after at least one . Subject with R/R PCNSL must have previously received at least high dose methotrexate. Subject with R/R PVRL must have received either intravenous high dose methotrexate or intraocular methotrexate (PVRL cohort). Subjects can have received radiotherapy or intensive chemotherapy with hematopoietic stem cell rescue as part of treatment of the PCNSL or PVRL.
  5. performance status 0 to 2.
  6. Estimated minimum of ≥ 2 months.
  7. R/R PCNSL subjects with evaluable disease on brain MRI.
  8. Able to swallow capsules (stomach tube not allowed)
  9. Adequate hematopoietic function:

    • of ≥ 1.0 G/L without G-CSF support for at least 7 days before screening
    • count of ≥ 50 G/L without platelet transfusion within 7 days before screening
    • ≥ 8.0 g/dL without RBC transfusion within 7 days before screening
  10. Adequate renal function: calculated by equation creatinine clearance > 40 ml/min. Subjects with calculated creatinine clearance > 40 and \< 60ml/min lenalidomide dose will be adjusted.
  11. Adequate liver function: Serum total level ≤ 2.0 mg/dl [34 µmol/L] (unless bilirubin rise is due to Gilbert's syndrome) and serum transaminases ( or ALT) ≤ 3 upper normal limits.
  12. Able to understand teratogenic risks of the treatment (Lenalidomide).
  13. Women of (WOCBP) should agree to use two reliable forms of simultaneously or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) for at least 28 days before starting study treatment, 2) while participating in the study, 3) dose interruptions, and 4) for at least 12 months after the final dose of rituximab, or for at least 12 months after the final dose of epcoritamab, or for at least 28 days after the final dose of lenalidomide . WOCBP should also agree to abstain from breastfeeding during study participation and for at least 4 months after discontinuation of all study treatments.
  14. WOCBP should have a negative serum (beta-hCG) pregnancy test at screening and a negative serum or urine pregnancy test before treatment administration on Day 1 of every cycle.
  15. Women should agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the entire study, until 12 months after the last administration of study treatment.
  16. Man who is sexually active with a female of and has not had a vasectomy should agree to use a highly effective / an acceptable method of birth control (ie, condom) and must agree not to donate sperm, until 28 days after the final dose of lenalidomide and/or until 12 months after the final dose of epcoritamab and rituximab.
  17. Subject covered by any social security system (France).
  18. Subject (or their legally acceptable representative/trusted person) who understands and speaks one of the country official languages unless local regulation authorizes independent translators.

Exclusion criteria

Exclusion criteria:

Subject who meets any of the following criteria should be excluded from enrollment in the study:

  1. T-cell lymphoma.
  2. Cerebral localization of a systemic lymphoma.
  3. Prior history of organ transplantation or other cause of severe immunodeficiency.
  4. Known (HIV) or Positive HTLV1 serology.
  5. Active Virus (HBV) infection (DNA PCR-positive) or active Virus (HCV) infection (RNA PCR-positive). Subjects with evidence of prior HBV infection but who are PCR-negative are permitted in the study but should receive prophylactic antiviral therapy. Subjects who received treatment for HCV infection that was intended to eradicate the virus may participate if hepatitis C RNA levels are undetectable.
  6. Persistent SARS-CoV-2 infection. Subjects who have had or currently have a SARS-CoV-2 infection must demonstrate symptom resolution and provide a negative nasopharyngeal PCR test at time of inclusion. Both of these requirements must be met for the subject to be considered clear of the virus.
  7. Impossibility to follow the calendar of exams because of geographic, social, or psychological reasons.
  8. Active other than the one treated in this Study. Prior history of malignancies (other than inclusion diagnosis) unless the subject has been free of the disease for ≥ 2 years. However, subjects with the following history/concurrent conditions are allowed:

    1. Non-invasive basal cell or epidermoid carcinoma
    2. In situ Carcinoma of the cervix
    3. In situ Carcinoma of the breast
    4. Non-invasive, superficial bladder cancer
    5. Incidental histologic finding of prostate cancer (T1a or T1b) using the tumor, nodes, [TNM] clinical staging system
    6. Any curable cancer with a complete response of >2 years duration
  9. Known or suspected to the active substance or to any of the .
  10. Any previous treatment with CAR-T therapy within 30 days prior to enrollment.
  11. Receiving therapy, including more than the equivalent of 20 mg of prednisolone daily, unless for control of lymphoma or intermittent prophylaxis/treatment of allergic reactions.
  12. Any previous treatment with a bispecific antibody targeting CD3 and CD20 and/or with lenalidomide, regardless of the time and duration.
  13. Seizure disorder requiring anti-epileptic therapy unless related to lymphoma.
  14. Vaccination with live, attenuated vaccines within 28 days prior of enrollment (except severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine). Examples of include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. Experimental and/or non-authorized SARS-CoV-2 vaccinations are not allowed.
  15. Use of any standard or experimental anti-cancer drug therapy within 28 days of the start (Day 1) of study treatment.
  16. Major surgery within 4 weeks prior to enrollment
  17. cardiovascular disease, including:

    1. Myocardial infarction within 1 year prior to enrollment, or unstable or uncontrol disease/condition related to or affecting cardiac function (e.g., unstable angina, congestive heart failure, Class III-IV) cardiac arrhythmia ( Version 5.0 Grade 2 or higher), or clinically significant abnormalities.
    2. Stroke within 6 months prior to enrollment.
  18. Screening 12-lead ECG showing a baseline as corrected by Fridericia's formula (QTcF) >470 msec.
  19. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection requiring systemic treatment at time of enrollment.
  20. to all uric acid lowering agents.
  21. Clinically significant liver disease, including active hepatitis, current alcohol abuse, or cirrhosis.
  22. Active tuberculosis or history of treatment for active tuberculosis within the past 12 months.
  23. Receiving immunostimulatory agent.
  24. Prior hematopoietic stem cell transplantation.
  25. Any significant medical conditions, laboratory abnormality or psychiatric illness likely to interfere with participation in this clinical study (according to the investigator's decision).
  26. Subject deprived of his/her liberty by a judicial or administrative decision.
  27. Subject hospitalized without consent.
  28. Adult subject under legal protection.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    experimental/epcoritamab

    Investigational Medicinal Product (IMP): Epcoritamab will be used during induction phase and Maintenance phase. Auxiliary Medicinal Products (AMP): Rituximab and Lenalidomide Standard use for AMP is: Induction: At cycle 1: Rituximab IV 375mg/m2 Day 1, 8, 15, 22; Lenalidomide 20mg oral route Day 1-Day 21 At cycle 2-3: Day 1: rituximab IV 375mg/m2; Lenalidomide 20mg oral route Day 1-Day 21 At cycle 4-8: Day 1: rituximab IV 375mg/m2; Lenalidomide 20mg oral route Day 1-Day 21 Maintenance: At cycle 9-20: Day 1: Lenalidomide 20mg oral route Day 1-D21 (12 cycles corresponding to one year of maintenance treatment)

    Drug: Epcoritamab

Interventions

  • Epcoritamab Investigational Medicinal Product (IMP): Epcoritamab will be used during induction phase and Maintenance phase.

06

What researchers measure

Primary outcomes

  1. The best Objective Response rate (ORR) in the R/R PCNSL cohort

    Objective Response rate

    Time frame: after 8 months or before in case of permanent treatment discontinuation

Secondary outcomes

  1. Objective response rate (CR + CRu + PR)

    Objective response rate

    Time frame: after 8 months or before in case of permanent treatment discontinuation

  2. Best objective response rate (CR + CRu + PR) in the PVRL cohort

    Objective response rate

    Time frame: after 8 months or before in case of permanent treatment discontinuation

  3. Objective response rate (CR + CRu + PR) in the PVRL cohort

    Objective response rate

    Time frame: after 8 months or before in case of permanent treatment discontinuation

  4. Best complete response rate (CR+CRu)

    Best complete response rate

    Time frame: after 8 months or before in case of permanent treatment discontinuation

  5. Time to objective response (TTR) according to IPCG recommendations

    Time to objective response

    Time frame: 44 months after first patient in

  6. Progression-free survival (PFS) according to IPCG recommendations

    Progression-free survival

    Time frame: 56 months after first patient in

  7. Duration of response (DOR) according to IPCG recommendations

    Duration of response

    Time frame: 56 months after first patient in

  8. Overall Survival (OS)

    Overall Survival

    Time frame: 56 months after first patient in

  9. Time to next treatment (TTNT)

    Time to next treatment

    Time frame: 56 months after first patient in

  10. Incidence and severity of AEs, special focus on ICANS, CRS and TLS

    Incidence and severity

    Time frame: 56 months after first patient in

  11. Incidence and severity of changes in laboratory values

    Incidence and severity

    Time frame: 44 months after first patient in

  12. Incidence of dose delay and treatment discontinuation

    Incidence of dose delay

    Time frame: 44 months after first patient in

  13. Time to deterioration in physical functioning - EORTC QLQ-C30

    EORTC QLQ-C30 quality of life questionnaire. 30 questions using a scale of 4: from 1 (not at all) to 4 (very much). (lower score (worse): 120 and higher score (better): 30)

    Time frame: 44 months after First Patient In

  14. Cognitive evaluation with MoCA test

    10 questions / topics with different scores (between 1 and 6) and with a total score /30" (lower score (worse): 0 and higher score (better)

    Time frame: 56 months after first patient in

  15. Time to deterioration in physical functioning - QLQ-HG29

    QLQ-HG29 Questionnary of Life: 29 additional questions using a scale of 4: from 1 (not at all) to 4 (very much). (lower score (worse): 116 and higher score (better): 29)

    Time frame: 44 months after First Patient In

  16. Cognitive evaluation with with BEARNI test

    5 questions / topics with different scores (between 5 and 8) and with a total score /30" (lower score (worse): 0 and higher score (better): 30)

    Time frame: 56 months after first patient in

07

Study locations

9 of 13 sites recruiting
  • INSTITUT BERGONIE - Service d'Oncologie Médicale
    Bordeaux, France
    Recruiting
    • Dr. SCHMITT · Contact
  • INSTITUT D'HEMATOLOGIE DE BASSE NORMANDIE - Service Hématologie
    Caen, France
    Recruiting
    • Dr. DAMAJ · Contact
  • CHU ESTAING - Service Thérapie Cellulaire et Hématologie Clinique
    Clermont-Ferrand, France
    Recruiting
    • Dr. MOLUCON-CHABROT · Contact
  • CHU DE LILLE - HOPITAL CLAUDE HURIEZ - Service des Maladies du Sang
    Lille, France
    Recruiting
    • Pr. MORSCHHAUSER · Contact
  • CHR DE MARSEILLE - CHU TIMONE - Service de Neuro-Oncologie
    Marseille, France
    Active, not recruiting

    Not enrolling at this site.

  • CHRU DE NANCY - HOPITAL CENTRAL - Service de Neurologie
    Nancy, France
    Active, not recruiting

    Not enrolling at this site.

  • GHU PITIE-SALPETRIERE - CHARLES FOIX - Service Neurologie
    Paris, France
    Recruiting
    • Dr. HOUILLIER · Contact
  • HOPITAL DE LA PITIE SALPETRIERE - Service Hématologie Clinique
    Paris, France
    Active, not recruiting

    Not enrolling at this site.

  • CHU LYON-SUD - Hématologie Clinique
    Pierre-Bénite, France
    Recruiting
    • Pr. Ghesquieres · Contact
  • CHU PONTCHAILLOU - Hématologie Clinique
    Rennes, France
    Active, not recruiting

    Not enrolling at this site.

  • INSTITUT CURIE - SITE SAINT-CLOUD - Service Hématologie
    Saint-Cloud, France
    Recruiting
    • Dr. GILBERT · Contact
  • IUCT ONCOPOLE - Service Hématologie
    Toulouse, France
    Recruiting
    • Dr. OBERIC · Contact
  • CHU BRETONNEAU - Service Cancérologie - Hématologie et Thérapie Cellulaire
    Tours, France
    Recruiting
08

References and documents

Publications

  • Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Molucon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)dagger. Ann Oncol. 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032. PubMed 30698644 ↗
  • Top FU, Usta T, Gucesan S. [Determining headache characteristics among Health Sciences Faculty students and evaluating the cultural beliefs affecting their treatment selection(s)]. Agri. 2010 Jan;22(1):13-20. Turkish. PubMed 20209410 ↗
  • Houillier C, Dureau S, Taillandier L, Houot R, Chinot O, Molucon-Chabrot C, Schmitt A, Gressin R, Choquet S, Damaj G, Peyrade F, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Al Jijakli A, Morel P, Waultier A, Paillassa J, Chauchet A, Gastinne T, Laadhari M, Plissonnier AS, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C; LOC Network for CNS Lymphoma. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study. J Clin Oncol. 2022 Nov 10;40(32):3692-3698. doi: 10.1200/JCO.22.00491. Epub 2022 Jul 14. PubMed 35834762 ↗
  • O'Neill BP, Decker PA, Tieu C, Cerhan JR. The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma. Am J Hematol. 2013 Dec;88(12):997-1000. doi: 10.1002/ajh.23551. Epub 2013 Sep 12. PubMed 23873804 ↗
  • Bauchet L, Rigau V, Mathieu-Daude H, Figarella-Branger D, Hugues D, Palusseau L, Bauchet F, Fabbro M, Campello C, Capelle L, Durand A, Tretarre B, Frappaz D, Henin D, Menei P, Honnorat J, Segnarbieux F. French brain tumor data bank: methodology and first results on 10,000 cases. J Neurooncol. 2007 Sep;84(2):189-99. doi: 10.1007/s11060-007-9356-9. Epub 2007 Apr 13. PubMed 17431547 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jan 2028, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
Apr 17, 2025
StartActual
Sep 22, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2030
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06931652
Lead sponsor
The Lymphoma Academic Research Organisation
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Apr 17, 2025
Start date
Sep 22, 2025
Primary completion
Jan 2028 (estimated)
Completion
Jan 2030 (estimated)
Last update
Jun 15, 2026

Study contacts

Project Management
Contact
e-revri@lysarc.org
04 72 66 93 33 ext. +33
Hervé Pr. Ghesquieres, MD
principal investigator · HCL - Hôpital Lyon Sud - Service d'Hématologie - 165 Chemin du Grand Revoyet, 69310 Pierre-Bénite - France
Gabriel Dr. Antherieu, MD
principal investigator · HCL - Hôpital Lyon Sud - Service d'Hématologie - 165 Chemin du Grand Revoyet, 69310 Pierre-Bénite - France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epcoritamab

Start the discussion